Infliximab loading optimisation

XPS Results
XPS was performed using an AXIS Ultra DLD spectrometer (Kratos Analytical, UK) equipped with a monochromatic Al Kα radiation source (hν -1486.6 eV) at a power of 225 W. The pass energy for survey spectra, recorded over the energy range 0 -1000 eV, was 160 eV with 0.5 eV step size and the pass energy for high-resolution C 1s spectra was 20 eV with 0. Infliximab loaded and blank pSi-Ox surfaces were investigated via XPS to confirm the presence of protein in the pores after loading. Table 2 shows the at. % of elements found on both surfaces. 
L929 BioAssay
To screen the optimal release conditions for the Infliximab loaded into pSi MPs we used a bioassay based on L929 cells and their sensitivity to TNF-α. TNF- is cytotoxic to L929 fibroblasts and hence can be used as a cell-based bioassay for TNF- human TNF-α for 10 minutes at 37˚C, and then added to L929 cells. MTT assay was used to measure L929 cell viability using absorbance at 570 nm. Data is presented as mean +/-one standard deviation (n = 4). Figure S7 : Effect of pH and temperature on the functionality of Infliximab.
ToF-SIMS
Stability of Infliximab at various pH, temperatures and incubation times
Infliximab (1 mg/mL) was incubated in pH adjusted PBS at 4 o C (A), 25 o C (B) and 37 o C (C). Samples were then incubated with 1 µg/mL human TNF-α for 10 minutes at 37˚C, and then added to L929 cells. MTT assay was used to measure L929 cell viability using absorbance at 570 nm. Data is presented as mean +/-one standard deviation (n = 3). Data is presented as a % of cell viability.
